Codexis (CDXS +1%) and collaboration partner Nestlé Health Science (OTCPK:NSRGY) have agreed to advance lead enzyme therapy candidate CDX-7108 for the potential treatment of an unspecified gastrointestinal (GI) disorder.
Concurrently, the companies have extended their agreement through 2021 to support the discovery of additional candidates.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.